Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for
Local Patients With Chronic Kidney Disease
Event to Feature 'Kidney-Friendly' Recipes
HOUSTON, Dec. 7 /PRNewswire-FirstCall/ -- Celebrity chef Katie Lee Joel
and Shire Pharmaceuticals (Nasdaq: SHPGY), the global biopharmaceutical
company, today announced that Katie will be conducting a free cooking
demonstration at the Doubletree Hotel Houston Downtown from 1-3 PM tomorrow,
Saturday, December 8th, for local patients with chronic kidney disease (CKD)
and their families.
During the demonstration, Katie will demonstrate to patients and their
family members how to prepare recipes from Shire's 2007 edition of the Kidney
Friendly Comfort Foods cookbook. Additionally, attendees will be able to
sample some of Katie's recipes, as well as receive a complimentary copy of the
new cookbook, which will be available for free after the event, by visiting
www.FOSRENOL.com or by calling (866) 896-6152.
Kidney disease is an issue close to Katie's heart because her grandfather
was a dialysis patient for several years. Although the family was worried
about his health, her grandfather was more concerned with the restrictions the
condition put on his diet. To help keep him healthy and happy, Katie and her
grandmother adapted many of their family's traditional recipes so that Katie's
grandfather and the rest of the family could still eat the meals that they
loved.
"I know how difficult managing kidney disease can be, which is why I was
so excited to contribute my recipes to Shire's second volume of the Kidney
Friendly Comfort Foods cookbook," said Katie. "It's especially important for
CKD patients to have holiday recipes that meet their dietary needs, so that
they don't feel left out during the customary family meals around this time of
year. Through the cookbook and tomorrow's demonstration, I want to show
patients that cooking kidney- and diabetes-friendly food is not a sentence to
boring food, and that these tasty meals can be enjoyed by the entire family
year round."
Katie will be joined tomorrow by MAR Catering's Corporate Executive Chef
Rufino Rengifo and renal dietitian and certified diabetes educator Marianne
Hutton, who helped develop Kidney Friendly Comfort Foods, Volume II. In
addition to demonstrating recipes from the cookbook, Katie and Rufino will
show attendees how to cook a kidney-friendly version of a holiday recipe
developed by Rufino, while Marianne will provide helpful dietary tips.
"I have had previous experience modifying recipes for individuals with
certain health conditions, and was excited to work with Katie and Shire on
this kidney-friendly cooking demonstration," said Rufino. "Although I adjusted
my recipe for turkey breast served with cranberry sauce to specifically
address CKD patients' dietary requirements, the recipe remains both delicious
and appropriate for the holiday season."
Chronic kidney disease is a growing problem in the United States. In fact,
approximately 20 million adult Americans have some form of CKD and almost
500,000 of these people have developed the most advanced form of kidney
disease, CKD Stage 5, and currently are receiving dialysis. Almost half of
newly diagnosed kidney patients on dialysis developed kidney disease because
of diabetes.
It is important for people with CKD Stage 5 to follow a low phosphorus
diet because most dialysis patients will develop hyperphosphatemia (high serum
phosphorus levels in the blood). Excess phosphorus in the blood can be
associated with serious consequences, including mineral deposits in the heart
and blood vessels, bone disease and even death. Because phosphorus is found in
so many foods, patients often cannot reach target blood phosphorus levels
through dietary restriction and dialysis alone, and they generally treat
hyperphosphatemia by taking phosphate binders, such as FOSRENOL(R) (lanthanum
carbonate), at meals. Phosphate binders "soak up" phosphorus in the
gastrointestinal tract before it can be absorbed into the bloodstream, thereby
helping patients maintain target blood phosphorus levels.
"We know the holidays can make it even more difficult for CKD Stage 5
patients with hyperphosphatemia to comply with their prescribed dialysis,
diet, and phosphate binder treatment. The dietary tips that will be discussed
at tomorrow's event, coupled with resources such as the cookbook, can help
patients overcome the challenges they face managing their disease everyday,"
said Joseph Schlitz, vice president, US Renal Commercial Operations, Shire
Pharmaceuticals. "Combining these resources with FOSRENOL, an effective
phosphate binder with a well-established safety profile, provides patients
with the tools they need to achieve and maintain target phosphate levels
during the holidays and all year round."
Hyperphosphatemia is difficult to treat because it requires patients to
follow a special diet, and comply with a prescribed binder therapy regimen
that may require up to 12 pills a day, while attending dialysis sessions.
However, patients with hyperphosphatemia may be able to reduce their pill
burden to as few as one tablet with each meal with treatments such as
FOSRENOL. (Dosing based on as few as three tablets per day. Number of meals
per day may vary. To achieve certain doses, additional tablets may be
required.)
To obtain your free copy of the 2007 Kidney Friendly Comfort Foods, Volume
II: Eating Well for Chronic Kidney Disease Patients, Including Those With
Diabetes cookbook, please visit www.FOSRENOL.com or call (866) 896-6152.
About Katie Lee Joel
Katie is currently writing her first cookbook, to be published next year
by Simon and Schuster. The book is a compilation of updated classics from her
archive of family recipes using the best seasonal ingredients. Katie regularly
appears on Extra as a special correspondent, covering everything from red
carpet events to food to fashion. Katie is a contributing editor to Gotham
magazine, and her culinary and lifestyle column, Katie's Kitchen, is published
weekly in its sister magazine, Hamptons.
Katie was the first season host of Bravo's hit "Top Chef," a reality
competition series for the culinary arts. In July 2005, with partner Aleishall
Girard, Katie co-created the Web site www.oliveandpeach.com, a site dedicated
to food and the importance of "conscious consumption." She resides in the New
York area with her husband, musician Billy Joel.
FOSRENOL
FOSRENOL is indicated to reduce serum phosphate in patients with end stage
renal disease (ESRD) -- also known as CKD Stage 5.
FOSRENOL is an effective, non-calcium, phosphate binder that reduces high
phosphorus levels in ESRD patients. FOSRENOL is formulated as an easy-to-use,
unflavored, chewable tablet that can be taken without water, an important
consideration for ESRD patients who must restrict their fluid intake.
FOSRENOL is available in a broad range of dosage strengths consisting of
500-milligram (mg), 750-mg, and 1-g tablets. Patients taking FOSRENOL can
achieve serum phosphorus target levels with as few as three tablets per day.
(Dosing based on three meals per day. Number of meals per day may vary. To
achieve certain doses, additional tablets may be required.)
FOSRENOL has a high affinity for phosphate and works by binding to dietary
phosphorus in the gastrointestinal tract. Once bound, the FOSRENOL/phosphorus
complex cannot pass into the bloodstream and is eliminated from the body,
thereby decreasing mean serum phosphorus levels.
To date, FOSRENOL has been clinically tested in more than 5,200 patients
globally, with nearly 1,000 of these patients having been followed for more
than one year. In addition, more than 87,000 patients have been prescribed
FOSRENOL in the US alone. FOSRENOL has the most extensive long-term safety
data package of any phosphate binder and is generally well tolerated. Trials
involving patients treated with FOSRENOL showed sustained serum phosphorus
reduction in a majority of patients, with some patients being followed over a
six-year duration.
FOSRENOL is now available in 23 countries, including Canada, France,
Germany, Italy, and the UK, and continues to be launched in new markets around
the world.
Important Safety Information
The most common adverse events were gastrointestinal, such as nausea and
vomiting, and generally abated over time with continued dosing. The most
common side effects leading to discontinuation in clinical trials were
gastrointestinal events (nausea, vomiting, and diarrhea). Other side effects
reported in trials included dialysis graft complications, headache, abdominal
pain, and hypotension. Although studies were not designed to detect
differences in risk of fracture and mortality, there were no differences
demonstrated in patients treated with FOSRENOL compared to alternative therapy
for up to three years. The duration of treatment exposure and time of
observation in the clinical program were too short to conclude that FOSRENOL
does not affect the risk of fracture or mortality beyond three years. While
lanthanum has been shown to accumulate in the GI tract, liver, and bone in
animals, the clinical significance in humans is unknown. Patients with acute
peptic ulcer, ulcerative colitis, Crohn's disease, or bowel obstruction were
not included in FOSRENOL clinical studies. Caution should be used in patients
with these conditions. FOSRENOL should not be taken by patients who are
nursing or pregnant. FOSRENOL should not be taken by patients who are under 18
years of age.
For Full Prescribing Information on FOSRENOL, please visit
www.fosrenol.com.
SHIRE PLC
Shire's strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the specialist
physician. Shire focuses its business on attention deficit and hyperactivity
disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and
renal diseases. The structure is sufficiently flexible to allow Shire to
target new therapeutic areas to the extent opportunities arise through
acquisitions. Shire's in-licensing, merger and acquisition efforts are focused
on products in niche markets with strong intellectual property protection
either in the US or Europe. Shire believes that a carefully selected portfolio
of products with strategically aligned and relatively small-scale sales forces
will deliver strong results. For further information on Shire, please visit
the Company's website: www.shire.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995
Statements included herein that are not historical facts are forward-
looking statements. Such forward-looking statements involve a number of risks
and uncertainties and are subject to change at any time. In the event such
risks or uncertainties materialize, Shire's results could be materially
affected. The risks and uncertainties include, but are not limited to, risks
associated with: the inherent uncertainty of pharmaceutical research; product
development including, but not limited to, the successful development of
JUVISTA(R) (Human TGFa3) and GA-GCB (velaglucerase alfa); manufacturing and
commercialization including, but not limited to, the launch and establishment
in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit
and Hyperactivity Disorder ("ADHD")); the impact of competitive products
including, but not limited to, the impact of those on Shire's ADHD franchise;
patents including, but not limited to, legal challenges relating to Shire's
ADHD franchise; government regulation and approval including, but not limited
to, the expected product approval date of INTUNIV(TM) (guanfacine extended
release) (ADHD); Shire's ability to secure new products for commercialization
and/or development; and other risks and uncertainties detailed from time to
time in Shire plc's filings with the Securities and Exchange Commission,
particularly Shire plc's Annual Report on Form 10-K for the year ended
December 31, 2006.
SOURCE Shire Pharmaceuticals
Sarah Stearns of Porter Novelli, +1-212-601-8413, or cell, +1-617-447-8878,
sarah.stearns@porternovelli.com
